Venous thromboembolism prophylaxis after major surgery for urological cancer: Are we prescribing it correctly?
BAUS ePoster online library. Henry M. Jun 25, 2019; 265260; CU-7
Ms. Mei-Ling Henry
Ms. Mei-Ling Henry
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
This audit aimed to assess compliance with national guidance and ascertain current practice at a single centre for urology, regarding the prescription of mechanical and pharmacological thromboprophylaxis after major urological surgery for cancer.

Retrospective data were collected for consecutive patients undergoing major abdominal surgery for urological cancer at a single centre for urology over a 31 day period using local electronic theatre management and prescribing systems. National guidelines for thromboprophylaxis were used to set criteria and standards.

24 patients with a suspected or confirmed cancer diagnosis were operated over a 31 day period. 100.0% of patients had enoxaparin prescribed as an inpatient on their discharge summary (24/24). 58.3% of patients were prescribed 28 days of enoxaparin (14/24). 37.5% of patients had an alternative length of extended pharmacological prophylaxis, ranging from 27 to 31 days (9/24). 20.8% of patients were prescribed anti-embolism stockings as an inpatient and 16.7% of patient were prescribed anti-embolism stockings for discharge (4/24). When course length for anti-embolism stockings was specified on the discharge summary it was found to match the course length of the enoxaparin prescribed.

Excellent overall compliance with prescription of pharmacological thromboprophylaxis was identified, although mechanical thromboprophylaxis was highlighted as an area requiring improvement. A further cycle of data collection to collect data on instructions given in operative notes and results will be presented locally. Further to this a re-audit will be planned and is expected to be complete by June 2019.

Venous thromboembolism (VTE) is an important cause of morbidity and mortality in patients admitted to hospital. The risk of developing VTE is affected by patient factors, such as co-morbidities and age, and admission related factors, such as surgical
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings